|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:affects
|
central nervous system
|
|
gptkbp:alsoKnownAs
|
stimulants
|
|
gptkbp:category
|
controlled substances
psychoactive drugs
nervous system drugs
|
|
gptkbp:cause
|
tolerance
dependence
withdrawal symptoms
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
anxiety disorders
|
|
gptkbp:form
|
gptkb:tablet
gptkb:water
capsule
powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
psychostimulants
|
|
gptkbp:improves
|
gptkb:energy
attention
alertness
|
|
gptkbp:include
|
gptkb:ephedrine
gptkb:modafinil
gptkb:methylphenidate
gptkb:pseudoephedrine
cocaine
amphetamine
caffeine
|
|
gptkbp:legalStatus
|
varies by country
|
|
gptkbp:mechanismOfAction
|
increase dopamine
increase norepinephrine
increase serotonin
|
|
gptkbp:medicalUse
|
gptkb:attention_deficit_hyperactivity_disorder
obesity
narcolepsy
|
|
gptkbp:regulates
|
controlled substances in many countries
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
intranasal
|
|
gptkbp:sideEffect
|
addiction
anxiety
increased heart rate
insomnia
|
|
gptkbp:usedFor
|
cognitive enhancement
performance enhancement
recreational purposes
|
|
gptkbp:bfsParent
|
gptkb:Sodium-dependent_serotonin_transporter
gptkb:neurotransmitter_transporter_family
gptkb:dopaminergic_signaling_pathway
gptkb:noradrenaline_transporter
gptkb:ADHS
|
|
gptkbp:bfsLayer
|
8
|